Literature DB >> 3040216

Primary liver cancer in Japan. Sixth report. The Liver Cancer Study Group of Japan.

.   

Abstract

The Liver Cancer Study Group of Japan statistically analyzed 4658 cases of primary liver cancer diagnosed from January 1, 1980 to December 31, 1981 in over 400 hospitals throughout the country. The study group comprised 2038 cases of hepatocellular carcinoma, 146 of cholangiocarcinoma, 33 of mixed carcinoma, 30 of hepatoblastoma, six of sarcoma, and 33 others. In 2286 cases (49.1%) a histologic diagnosis was available. The survey, based mostly on the histologically proven cases, describes histologic features of the tumors, grade of anaplasia and growth patterns of the tumor cells, pathology in noncancerous portions of the liver, distant metastases, medical history, frequency of hepatitis in the history, frequency of positive HBsAg and anti-HBs, age distribution, subjective symptoms, radiographic features (angiogram, scintiscan, computed tomography), ultrasonography, surgical procedures, extent of hepatic resection, and survival.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040216     DOI: 10.1002/1097-0142(19870915)60:6<1400::aid-cncr2820600639>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

1.  Effect of arterial administration of a high molecular weight anti-tumor agent, styrene maleic acid neocarzinostatin, for multiple small liver cancer--a pilot study.

Authors:  K Ikeda; S Saitoh; Y Suzuki; A Tsubota; I Koida; M Kobayashi; Y Arase; K Chayama; N Murashima; H Kumada
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

2.  Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma.

Authors:  Young Je Park; Do Hoon Lim; Seung Woon Paik; Kwang Cheol Koh; Joon Hyoek Lee; Moon Seok Choi; Byung Chul Yoo; Hee Rim Nam; Dong Ryul Oh; Won Park; Yong Chan Ahn; Seung Jae Huh
Journal:  J Gastroenterol       Date:  2006-12-08       Impact factor: 7.527

Review 3.  Hepatocellular carcinoma. A worldwide problem and the major risk factors.

Authors:  R G Simonetti; C Cammà; F Fiorello; F Politi; G D'Amico; L Pagliaro
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

4.  Relationship between general or specific immunoreactivity and prognosis in postoperative patients with hepatocellular carcinoma.

Authors:  H Yamasaki; E Okamoto; T Komatsu; Y Manabe; S Shinka
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Amplification of BCR protein associated with oncogenesis in human hepatocellular carcinoma.

Authors:  Y Miyazaki; T Mitsuma; T Ichida; H Odazima; K Ishihara; H Asakura
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

6.  Needle tract implantation of hepatoblastoma after percutaneous needle biopsy: report of a case.

Authors:  Tatsuaki Sumiyoshi; Yasuo Shima; Ritsuo Nishiuchi; Kiyoshi Sasaki; Akihito Kouzuki; Yoshihiro Noda; Yasuhiro Hata; Kiminobu Uka
Journal:  Surg Today       Date:  2013-04-19       Impact factor: 2.549

7.  Selection of therapeutic modalities for hepatocellular carcinoma in patients with multiple hepatic lesions.

Authors:  M Monden; M Sakon; M Gotoh; T Kanai; K Umeshita; K S Wang; M Sakurai; C Kuroda; J Okamura; T Mori
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Significance of multidisciplinary therapy for hepatocellular carcinoma.

Authors:  Y Kawarada; T Imai; M Iwata; H Yokoi; T Noguchi; R Mizumoto
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Clinical evaluation of intermittent arterial infusion chemotherapy with an implanted reservoir for hepatocellular carcinoma.

Authors:  K Nakamura; S Takashima; K Takada; K Fujimoto; T Kaminou; H Nakatsuka; K Minakuchi; Y Onoyama
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  [Palliative therapy of primary liver tumors].

Authors:  C Kelm; K Henneking; T Zimmermann; M Vollerthun; W Padberg
Journal:  Langenbecks Arch Chir       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.